Table 3.
Unadjusted and adjusted logistic regression analyses of factors associated with DAA-based therapy uptake among recent PWID with chronic HCV infection (n=611), Vancouver, Canada (April 2015 – November 2017)
| Characteristic | Unadjusted OR (95% CI) | Adjusted OR (95% CI) |
|---|---|---|
| Age (per year older) | 1.05 (1.02 – 1.07)† ‡ | 1.02 (0.99 – 1.05) |
| Male gender (yes vs. no) | 1.56 (0.95 – 2.64)† | 1.38 (0.79 – 2.44) |
| White race (yes vs. no) | 1.73 (1.06 – 2.86)† ‡ | 1.73 (1.02 – 3.00)‡ |
| HIV-positive (yes vs. no) | 3.18 (1.95 – 5.97)† ‡ | 2.65 (1.57 – 4.57)‡ |
| ≥ Daily heroin injection (yes vs. no)* | 0.52 (0.29 – 0.88)† ‡ | 0.71 (0.38 – 1.27) |
| ≥ Daily cocaine injection (yes vs. no)* | 0.80 (0.27 – 1.92) | |
| ≥ Daily crack use (yes vs. no)* | 0.79 (0.32 – 1.70) | |
| ≥ Daily opioid analgesic use (yes vs. no)* | 1.14 (0.26 – 3.48) | |
| Syringe sharing (yes vs. no)* | 1.14 (0.26 – 3.48) | |
| High-risk drinking (yes vs. no)* | 0.57 (0.23 – 1.20) | |
| In addiction care (reference: none)* | ||
| OAT | 2.01 (1.15 – 3.67)† ‡ | 2.00 (1.11 – 3.78)‡ |
| Other treatment modalities | 1.49 (0.55 – 3.65) | 1.44 (0.51 – 3.72) |
| Ever received IFN-based therapy for HCV infection | 0.52 (0.12 – 1.49) | |
| In HCV-related care (yes vs. no)* | 2.12 (1.32 – 3.45)† ‡ | 1.44 (0.86 – 2.43) |
| Homelessness (yes vs. no)* | 0.37 (0.15 – 0.78)† ‡ | 0.74 (0.28 – 1.69) |
| Residency in the Downtown Eastside (yes vs. no)* | 0.63 (0.39 – 1.05)† | 0.76 (0.45 – 1.31) |
| Employment (yes vs. no)* | 1.43 (0.80 – 2.47) | |
| Prohibited income generation (yes vs. no)* | 0.54 (0.33 – 0.87)† ‡ | 0.78 (0.46 – 1.31) |
| Incarceration (yes vs. no)* | 0.29 (0.05 – 0.96)† ‡ | 0.50 (0.08 – 1.86) |
DAA, direct-acting antiviral; OAT, opioid agonist therapy.
*
Refers to the 6-month period prior to the interview
†
p<0.10 and included in the multivariable model
‡
p<0.05